Skip to main content
. 2020 Nov 6;124(3):587–594. doi: 10.1038/s41416-020-01140-9

Fig. 2. Survival times in the RASwt population that were per protocol accessible for tumour response (n = 352).

Fig. 2

Progression-free (a) and overall (b) survival in the RAS wild-type per-protocol population (N = 352). Bev bevacizumab, Cet cetuximab.